Table 6. Effects of the biologics administration during pregnancy on adverse pregnancy outcomes.
| Outcomes | No. | Univariate analysis | Multivariate analysis | |
|---|---|---|---|---|
| Unadjusted OR (95% CIs) | Adjusted ORa (95% CIs) | |||
| Fetal loss | ||||
| Biologics naïve group | 940 | Reference | Reference | |
| Biologics use during pregnancy | 29 | 0.307 (0.208–0.453) | 0.274 (0.183–0.411) | |
| Preterm delivery | ||||
| Biologics naïve group | 405 | Reference | Reference | |
| Biologics use during pregnancy | 60 | 1.968 (1.458–2.656) | 1.859 (1.353–2.554) | |
| Preeclampsia/eclampsia | ||||
| Biologics naïve group | 141 | Reference | Reference | |
| Biologics use during pregnancy | 18 | 1.568 (0.947–2.598) | 1.762 (1.033–3.006) | |
| Gestational diabetes mellitus | ||||
| Biologics naïve group | 1,323 | Reference | Reference | |
| Biologics use during pregnancy | 101 | 0.879 (0.687–1.125) | 0.903 (0.697–1.169) | |
| Intrauterine growth retardation | ||||
| Biologics naïve group | 88 | Reference | Reference | |
| Biologics use during pregnancy | 24 | 3.471 (2.176–5.537) | 3.487 (2.109–5.767) | |
| Cesarean section | ||||
| Biologics naïve group | 1,118 | Reference | Reference | |
| Biologics use during pregnancy | 145 | 2.047 (1.621–2.584) | 1.831 (1.430–2.344)b | |
CI = confidence interval, OR = odds ratio, FDA = Federal Drug Administration.
aAdjusted for recorded diagnosis, age, Charlson Comorbidity Index, previous long-term use of glucocorticoids, non-steroid anti-inflammatory drugs, and FDA category X drugs, previous history of infertility, and abortion.
bAdjusted for recorded diagnosis, age, Charlson Comorbidity Index, previous long-term glucocorticoids use, non-steroidal anti-inflammatory drugs, and FDA category X drugs, previous history of infertility, abortion, and cesarean section.